



Post Authorisation Assessments

Vetoryl 10 mg Hard Capsules for Dogs Vm 10434/5006

•	27 February 2024	Change in qualitative composition of the immediate packaging for a solid pharmaceutical form for a finished product.
•	25 January 2024	<p>Change in the address or contact details of a manufacturer or supplier of the starting material, used in the manufacture of the active substance where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier.</p> <p>Change to comply with Ph. Eur. for the starting material used in the manufacture of the active substance.</p> <p>Changes to a test procedure for a reagent used in the manufacturing process of the active substance:– for a reagent, which does not have a significant effect on the overall quality of the active substance.</p> <p>Changes to the quality part of the dossier: Deletion of a test procedure for a reagent used in the manufacture of the active substance.</p> <p>Changes to the quality part of the dossier: Deletion of - a non-significant specification parameter of an active substance.</p> <p>Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible.</p> <p>Minor changes:– to an approved test procedure for the active substance.</p>
•	28 November 2023	One-off alignment of the product information with version 1 of the National QRD template.
•	25 August 2023	<p>Deletion of a non-significant specification parameter in the finished product specification.</p> <p>Deletion of a non-significant specification parameter in the finished product specification.</p> <p>Deletion of a non-significant specification parameter in the finished product specification.</p>
•	18 August 2023	Change to an approved stability protocol of the finished product.
•	August 2023	Minor changes:– to an approved test procedure for active substance, for the finished product, for the immediate packaging of the active substance or the finished product, or of a measuring or administration device.

•	08 February 2023	Deletion of a non-significant in-process test during the manufacture of the finished product.
•	23 January 2023	Editorial changes to part 2 of the dossier.
•	07 September 2022	Deletion of a non-significant in-process test during the manufacture of the finished product.
•	28 July 2022	Editorial changes to Part II B of the dossier for the 10 mg hard capsules. Editorial changes to Part II C of the dossier for the 5 mg and 60 mg hard capsules. Editorial changes to Part II F of the dossier for the 30 mg, 60 mg and 120 mg hard capsules.
•	29 March 2022	Deletion of a non-significant in-process test applied during the manufacture of the finished product.
•	16 November 2021	Addition of a new specification parameter to the specification with its corresponding test method of the finished product.
•	23 September 2021	Addition of a primary packaging site of the finished product. Addition of a secondary packaging site of the finished product.
•	09 February 2021	Submission of an updated Ph. Eur. TSE certificate of suitability for a starting material from an already approved manufacturer.
•	17 October 2019	Submission of an updated Ph. Eur. TSE certificate of suitability for a starting material from an already approved manufacturer. Submission of a new Ph. Eur. TSE certificate of suitability from a new / already approved manufacturer. Deletion of Ph. Eur. TSE certificates of suitability. Submission of an updated Ph. Eur. TSE certificate of suitability for a starting material from an already approved manufacturer.
•	24 September 2019	Changes to a test procedure for the finished product.
•	07 August 2019	Update to the ASMF.
•	18 June 2019	Addition of a manufacturer responsible for batch release including batch control/testing.
•	02 April 2019	Minor change to an approved test procedure for the active substance.
•	February 2019	Changes to an existing pharmacovigilance system as described in the DDPS.
•	08 February 2019	Introduction of a new site of manufacture.
•	01 August 2018	Change in RMS from UK to IE.
•	19 December 2017	Repeat Use application to add 2 new member states
•	02 February 2017	Changes to the labelling and package leaflet.
•	17 May 2016	Deletion of a TSE certificate. Submission of a new TSE certificate. Submission of an updated TSE certificate. Submission of a new TSE certificate. Submission of a new TSE certificate.
•	21 May 2015	Submission of updated Ph. Eur. Certificates of Suitability from an already approved manufacturer
•	01 May 2015	Change in name of a manufacturer of the active substance.

•	27 February 2015	Minor changes to an approved test procedure.
•	20 November 2014	Updates to the labelling and package leaflet.
•	10 October 2014	Change of MA holder address.
•	06 March 2014	Significant change to the SPC with regard to clinical data.
•	14 November 2013	To update the drug master file. Amendment to specifications of raw materials. Updates to manufacturing methods.
•	03 January 2013	Renewal procedure – UK as RMS.
•	03 June 2012	Submission of new or updated Ph. Eur Certificates of Suitability.
•	02 March 2012	Change in the manufacturer of the active substance.
•	09 December 2011	To change the ink used to mark the capsules.
•	01 April 2011	Changes to an existing pharmacovigilance system as described in the DDPS.
•	15 December 2010	Change of Distributor.
•	06 October 2010	To change the Marketing Authorisation Holder.
•	17 September 2010	Change in immediate packaging of the finished product.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	17 September 2010	Submission of new or updated Ph. Eur Certificates of Suitability.
•	23 October 2008	Change shelf life of finished product from 2 years to 3 years.
•	03 October 2008	Change active substance batch size